Financial Performance - The company's operating revenue for the first half of 2022 was ¥174,237,893, a decrease of 31.93% compared to ¥255,978,662.62 in the same period last year [24]. - The net loss attributable to shareholders for the first half of 2022 was ¥124,526,887.83, which is a 58.88% increase in loss compared to ¥78,376,720.20 in the previous year [24]. - The basic and diluted earnings per share for the first half of 2022 were both -¥0.2896, a decline of 58.86% from -¥0.1823 in the previous year [24]. - The weighted average return on net assets was -22.29%, compared to -11.59% in the same period last year, indicating a worsening financial performance [24]. - The total comprehensive loss for the first half of 2022 was -¥179,711,088.91, compared to -¥106,596,762.76 in the first half of 2021 [180]. - The company reported a significant increase in management expenses to ¥111,582,180.51, up from ¥103,970,335.05 in the previous year, indicating a rise of 7.8% [177]. - The net cash flow from operating activities improved by 26.63%, amounting to -¥202,922,140.48, compared to -¥276,570,704.48 in the same period last year [24]. - The company reported a total revenue of approximately 210.23 million for the first half of 2022, with a net profit of around 49.01 million, reflecting a significant growth compared to the previous period [94]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,550,033,291.44, reflecting a decrease of 7.19% from ¥1,670,098,071.00 at the end of the previous year [24]. - The net assets attributable to shareholders decreased by 21.86%, from ¥627,210,219.79 to ¥490,125,876.78 [24]. - The company's cash and cash equivalents decreased significantly from ¥254,135,962.85 to ¥92,605,024.96, indicating a reduction of about 63.6% [170]. - Total liabilities increased from CNY 896,422,764.68 to CNY 952,724,718.92, an increase of about 6.3% [172]. - The company's long-term equity investments decreased by 8.59% to ¥345,215,653 from ¥377,790,116 year-on-year [79]. - The total amount of retained earnings at the end of the current period was CNY 490,125,876 [196]. Cash Flow - The net cash flow from operating activities was -¥202,922,140.48, an improvement from -¥276,570,704.48 in the previous period, indicating a reduction in cash outflow [186]. - The total cash inflow from financing activities increased to ¥172,085,500.00, compared to ¥88,043,300.00 in the prior period, reflecting stronger financing efforts [187]. - The cash flow from investment activities was significantly lower, with cash inflow of ¥6,531,506.89 compared to ¥71,330,478.86 in the previous period, reflecting reduced asset disposals [186]. Strategic Focus and Innovations - The company is focusing on digital transformation driven by new infrastructure technologies such as 5G, cloud computing, big data, artificial intelligence, IoT, and blockchain [32]. - The company is actively involved in the development of a digital government service system, leveraging new technologies for comprehensive public service [36]. - The company has launched innovative payment solutions for various hospitals, enhancing the efficiency of medical payment processes [39]. - The company has introduced new technologies, including AI and blockchain, to enhance its service offerings and operational efficiency [41]. - The company is focusing on expanding its market presence through innovative healthcare solutions and strategic partnerships [54]. Risk Management - The management emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks [3]. - The report includes a detailed description of the company's risks and countermeasures in the management discussion section [3]. - The company has a comprehensive risk management strategy in place to address potential market and policy risks that could impact its business operations [96]. Corporate Governance and Shareholder Matters - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [4]. - The company has maintained a stable profit distribution policy to ensure reasonable returns to investors [112]. - The company completed a share transfer of 25% equity in a subsidiary, generating a transaction price of ¥3,875,000, with a net profit contribution of ¥119,800 [90]. - The company has implemented a share repurchase program, but specific details on the progress are not disclosed [151]. Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, including purchasing local agricultural products to support poverty alleviation efforts [114]. - The company aims to enhance public health service capabilities and ensure people's health through the promotion of smart hospitals and medical communities [35].

Financial Performance - The company's revenue for Q1 2022 was ¥72,422,850.80, representing a slight increase of 0.08% compared to ¥72,362,291.17 in the same period last year[2] - The net profit attributable to shareholders was -¥69,430,631.97, a decrease of 22.36% from -¥56,743,247.14 year-on-year[2] - The basic and diluted earnings per share were both -¥0.1615, a decrease of 24.23% from -¥0.1300 in the same period last year[2] - Net loss for Q1 2022 was CNY 92,100,064.17, compared to a net loss of CNY 73,273,233.34 in the same period last year[24] - The company reported a comprehensive loss of CNY 122,287,694.30, up from a loss of CNY 80,683,905.19 in the previous year[24] Cash Flow - The net cash flow from operating activities was -¥181,576,490.07, which is a decline of 12.75% compared to -¥161,036,894.15 in the previous year[2] - Cash inflow from operating activities totaled CNY 152,170,009.37, down from CNY 178,750,376.59 in the prior period[26] - The company reported a net decrease in cash and cash equivalents of 112,093,888.79 CNY, compared to a decrease of 81,864,470.09 CNY in the prior period[27] - Cash flow from investing activities decreased by 82.98%, primarily due to the previous year's receipt of funds from the sale of a subsidiary[8] - The cash outflow for investment activities totaled 2,448,784.64 CNY, compared to 1,146,681.50 CNY in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,532,381,086.40, down 8.25% from ¥1,670,098,071.00 at the end of the previous year[2] - The company's equity attributable to shareholders decreased by 15.86% to ¥527,707,111.10 from ¥627,210,219.79 at the end of the previous year[2] - The company’s total liabilities decreased to CNY 882,667,119.27 from CNY 896,422,764.68[21] - The company reported a total current liabilities of RMB 1,000,000,000.00, with short-term borrowings increasing to RMB 174,258,333.35 from RMB 105,162,789.54, an increase of about 65.7%[20] Expenses - Total operating costs increased to CNY 177,246,252.87 from CNY 153,497,372.53, with significant rises in sales expenses (CNY 29,363,508.04) and management expenses (CNY 52,611,169.77)[22] - The company reported a 68.46% increase in selling expenses, attributed to the hiring of additional sales personnel and increased sales efforts[6] - Research and development expenses for the quarter were CNY 50,425,959.72, an increase from CNY 45,551,652.83 in the previous year[22] Investments and Financing - The company completed the transfer of 25% equity in Fujian Xingmin Zhili Technology Co., Ltd., receiving a total of RMB 3.875 million[16] - The company also transferred 51% equity in Fujian Yilianzhong Electronic Technology Co., Ltd., receiving RMB 4.46873 million[16] - The company applied for a comprehensive credit facility of RMB 100 million from Xingye Bank, secured by properties and guarantees from the controlling shareholder[15] - The total cash inflow from financing activities was 155,052,500.00 CNY, an increase from 85,145,000.00 CNY in the prior period[27] Inventory and Receivables - The company reported a decrease in inventory from RMB 185,801,436.19 to RMB 145,958,038.15, a reduction of approximately 21.43%[19] - Accounts receivable stood at RMB 245,551,978.34, down from RMB 253,832,894.46, indicating a decrease of approximately 3.24%[19] Other Information - The company did not conduct an audit for the first quarter report[28] - The report was published by the Board of Directors on April 27, 2022[30] - The company received government subsidies during the quarter, with specific amounts disclosed in related announcements[15]

Financial Performance - The net profit attributable to shareholders for 2021 was -109.2681 million yuan, indicating a significant decline in operating performance [5]. - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-over-year increase of 15% compared to 2020 [18]. - The company's operating revenue for 2021 was ¥871,000,843.24, a decrease of 17.13% compared to ¥1,051,064,058.34 in 2020 [24]. - The net profit attributable to shareholders for 2021 was -¥109,268,110.47, representing a decline of 1,052.12% from a profit of ¥11,476,313.15 in 2020 [24]. - The net cash flow from operating activities for 2021 was -¥27,954,802.93, an improvement of 52.40% compared to -¥58,728,017.29 in 2020 [24]. - The total assets of the company increased to RMB 2.5 billion, reflecting a growth of 18% from the previous year [18]. - The company reported a negative basic earnings per share of -¥0.254 for 2021, compared to a positive ¥0.027 in 2020, marking a decline of 1,040.74% [24]. - The company achieved operating revenue of 871 million CNY, a year-on-year decrease of 17.13% [64]. - The company’s net profit attributable to shareholders was -109.22 million CNY, a year-on-year decline of 1,051.68% [64]. Market Expansion and Growth - User data showed an increase in active users by 25%, reaching a total of 5 million active users by the end of 2021 [18]. - The company provided a revenue guidance for 2022, expecting a growth rate of 20% year-over-year, targeting a revenue of approximately RMB 1.44 billion [18]. - The company expanded its market presence by entering three new provinces, aiming to increase its market share by 10% in these regions [18]. - The company is positioned to benefit from the increasing focus on digital transformation in public services, as the government pushes for a comprehensive internet-based service system [41]. - The company is actively involved in the development of policies that support the integration of commercial insurance with national medical insurance, enhancing the overall health care financing system [42]. - The company aims to leverage its mature products and development experience to expand its services to other provinces and regions, supporting the national medical reform initiative [37]. - The company is expanding its market presence in Northeast, Northwest, and Southwest regions, focusing on increasing customer base [68]. - The company plans to enter the Southeast Asian market in 2022, targeting a revenue contribution of 5% from this region [164]. Research and Development - The company invested RMB 100 million in R&D for new technologies, focusing on AI and big data analytics to improve service offerings [18]. - The company has established a robust research and development system, focusing on innovations in big data, artificial intelligence, and other emerging technologies to maintain competitive advantages [52]. - The company’s R&D investment in 2021 amounted to ¥223,100,576.21, representing 25.61% of its operating revenue, an increase from 19.21% in 2020 [93]. - The company is investing 50 million in R&D for new technologies aimed at enhancing user experience and operational efficiency [153]. - The company is investing 100 million RMB in R&D for new technologies, focusing on AI and big data analytics [173]. Strategic Initiatives - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [8]. - Management is focused on optimizing organizational structure and enhancing internal systems to promote sustainable development [5]. - The company is committed to developing solutions in the fields of healthcare, social security, and human resources, leveraging big data technologies [34]. - The company has implemented an open platform strategy since 2017, focusing on health medical big data and becoming a national demonstration enterprise in the elderly care industry [45]. - The company is committed to becoming a technology and service enterprise based on data chains, aligning with national strategies for digital and healthy China [47]. - The company is exploring potential acquisitions to enhance its service offerings and expand its market presence [170]. - The company is actively pursuing mergers and acquisitions to strengthen its competitive position in the market [141]. Governance and Management - The company has established a comprehensive governance structure in accordance with relevant laws and regulations, with no unresolved governance issues reported [129]. - The board of directors consists of 12 members, including 4 independent directors, and has held 19 meetings during the reporting period to ensure scientific decision-making [130]. - The company has maintained a clear separation from its controlling shareholder in terms of assets, personnel, and business operations, ensuring operational independence [134]. - The company has engaged in effective communication with investors, responding promptly to inquiries and participating in relevant training organized by regulatory bodies [131]. - The company has a diverse board of directors, with members holding various positions and responsibilities, ensuring a balanced governance structure [139]. - The company has undergone significant management changes, with multiple appointments and resignations among senior executives [147]. Operational Efficiency - The company is committed to enhancing its core technology competitiveness through increased investment in talent development and R&D [123]. - The company aims to reduce operational costs by 10% through efficiency improvements and process optimization [153]. - The company has implemented measures to prevent technology leakage, including patent applications and strict management of the R&D process [120]. - The company has established a customer-centric after-sales service system to mitigate operational risks associated with expanding product and service categories [120]. - The company has implemented new strategies to enhance operational efficiency and reduce costs [141]. Challenges and Risks - Increased operational costs, particularly labor costs, contributed to the decline in revenue, which was further impacted by the COVID-19 pandemic [5]. - The company faced risks related to slow progress on existing projects and a decrease in new contracts signed [78]. - The company recognizes the risk of market competition intensifying in the internet healthcare sector and is focused on leveraging its existing advantages to mitigate this risk [121]. - The company has focused on digital transformation in healthcare, aligning with national policies to enhance public health services [34]. - The company faced some business impacts due to localized COVID-19 outbreaks, but the demand in its industry is expected to gradually recover in 2022 [55].

证券代码：300096 证券简称：易联众 公告编号：2021-114 易联众信息技术股份有限公司 2021年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1. 公司董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人张曦、主管会计工作负责人陈东红及会计机构负责人（会计主管人员）苏元兴声明：保证季 度报告中财务报表的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 其他符合非经常性损益定义的损益项目的具体情况： □ 适用 √ 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项目 的情况说明 √ 适用 □ 不适用 | 本报告期 | | 本报告期比上年同期增 | 年初至报告期末 | 年初至 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥255,978,662.62, a decrease of 19.57% compared to ¥318,242,986.93 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2021 was -¥78,376,720.20, representing a decline of 69.39% from -¥46,269,822.24 in the previous year[22]. - The net cash flow from operating activities was -¥276,570,704.48, which is a 51.75% increase in cash outflow compared to -¥182,255,718.17 in the same period last year[22]. - The total assets at the end of the reporting period were ¥1,738,941,367.80, down 5.88% from ¥1,847,676,328.41 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 11.74% to ¥633,420,987.98 from ¥717,654,515.71 at the end of the previous year[22]. - The basic earnings per share for the first half of 2021 was -¥0.1823, a decrease of 69.42% from -¥0.1076 in the same period last year[22]. - The weighted average return on equity was -11.59%, a decline of 4.94% compared to -6.65% in the previous year[22]. - The company achieved operating revenue of 255.98 million yuan, a year-on-year decrease of 19.57%[45]. - Operating costs amounted to 151.28 million yuan, down 18.56% year-on-year[45]. - The company reported a net loss of CNY 102,889,955.23, compared to a net loss of CNY 53,459,503.82 in the first half of 2020, representing an increase in loss of 92.5%[176]. Investment and R&D - The company reported research and development expenses rose to CNY 93,315,494.37, an increase of 23.5% from CNY 75,585,919.93 in the previous year[174]. - The company has established a comprehensive product and technology R&D service and management system, focusing on innovation and customer satisfaction, with a strong core technology team[35]. - The company is focusing on new technologies such as big data, blockchain, and AI through dedicated research centers to enhance its product offerings[35]. - The company has committed to enhancing the efficiency of fundraising management to maximize investor rights protection[113]. - The company emphasizes innovation as a driving force for business development and continuously increases investment in technology talent and R&D[95]. Risk Management - The management emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks[4]. - The company faces risks related to technology and product development, emphasizing the need for continuous innovation[91]. - The company has established a robust internal control system to mitigate management risks associated with business upgrades[95]. - The company has adopted a proactive approach to risk management by hiring industry experts and conducting thorough market analysis[93]. Business Strategy and Operations - The company aims to provide comprehensive solutions and services in the fields of medical security, health, and social security, focusing on data-driven approaches[28]. - The company emphasizes its commitment to digital transformation in the healthcare sector, aligning with national health reform initiatives[28]. - The company is focusing on the integration of health insurance with its main businesses in medical security and social security, while strictly controlling risks in the insurance sector[34]. - The company has implemented an open platform strategy since 2017, focusing on health medical big data and becoming a national demonstration enterprise in the elderly care industry[32]. - The company has constructed a comprehensive management platform for the Shaxian General Hospital, facilitating unified management of personnel, finance, and resources[32]. - The company has been actively involved in the national healthcare reform, serving as a key integrator for information systems and a developer for the Fujian medical insurance management service platform[40]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[5]. - The company reported a 31.78% investor participation rate in its first extraordinary general meeting of 2021, indicating strong shareholder engagement[99]. - The actual controller and shareholders have fulfilled their commitments during the reporting period, with no overdue commitments as of the end of the reporting period[110]. - The company has terminated the issuance of A-shares to specific targets and withdrawn the application documents as of July 1, 2021[111]. - There were no stock incentive plans, employee stock ownership plans, or other employee incentive measures implemented during the reporting period[102]. Social Responsibility and Compliance - The company actively fulfills its social responsibilities while creating value for shareholders, ensuring transparency in shareholder meetings and information disclosure[106]. - The company and its subsidiaries are not classified as key pollutant discharge units by environmental protection authorities and have not faced administrative penalties for environmental issues during the reporting period[105]. - The company has been recognized as a recommended online training platform by the Ministry of Human Resources and Social Security, entering 12 provinces for online training[53]. Financial Position - Cash and cash equivalents decreased by 41.41% to ¥262.19 million, accounting for 15.08% of total assets, primarily due to negative net cash flow from operating activities[73]. - Accounts receivable increased by 9.83% to ¥289.78 million, representing 16.66% of total assets[73]. - Inventory rose significantly by 76.60% to ¥243.08 million, making up 13.98% of total assets, attributed to unrecognized project costs and increased goods dispatched[73]. - The company's total liabilities were CNY 956,800,178.63, slightly up from CNY 940,001,341.70 at the end of 2020, marking an increase of approximately 1.9%[168][169]. - The total equity attributable to the parent company decreased from CNY 717,654,515.71 at the end of 2020 to CNY 633,420,987.98, a decline of about 11.7%[169].

Financial Performance - The company's operating revenue for 2020 was ¥1,051,064,058.34, representing a 10.79% increase compared to ¥948,718,436.87 in 2019[17]. - The net profit attributable to shareholders for 2020 was ¥11,476,313.15, a 9.24% increase from ¥10,505,744.63 in the previous year[17]. - The basic earnings per share for 2020 was ¥0.027, up 12.50% from ¥0.024 in 2019[17]. - The company reported a quarterly revenue of ¥429,026,675.32 in Q4 2020, marking a significant increase from previous quarters[20]. - The company experienced a net profit of ¥51,657,574.41 in Q4 2020, a recovery from losses in earlier quarters[20]. - The revenue from the livelihood service sector was ¥924,156,509.52, accounting for 87.93% of total revenue, with a year-on-year growth of 2.98%[62]. - The financing service revenue decreased significantly by 84.27%, dropping to ¥6,676,531.28 from ¥42,456,973.94[62]. - The insurance brokerage sector saw a remarkable increase of 1,354.23%, with revenue rising to ¥119,554,303.24 from ¥8,221,167.29[62]. - The company reported a gross margin of 52.54% in the民生服务行业, with a slight increase of 0.01% compared to the previous year[65]. - The total operating costs for 2020 were 1,020,000,000 CNY, with a significant increase in costs related to technical services and data services, which rose by 1,642.91%[68]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥58,728,017.29, a significant decline of 192.49% compared to ¥63,494,197.92 in 2019[17]. - Operating cash inflow totaled CNY 1.16 billion in 2020, a 6.61% increase from CNY 1.08 billion in 2019, while cash outflow rose by 19.00% to CNY 1.21 billion[82]. - The net cash flow from investment activities decreased by 53.11%, mainly due to a significant cash recovery from investments in the previous year[84]. - The net cash flow from financing activities increased by 102.14%, primarily due to increased cash received from minority shareholders' investments in subsidiaries[84]. - The total investment during the reporting period was 67,085,000.00, an increase of 17.85% compared to the previous year's investment of 56,925,007.09[92]. - The company reported an investment loss of -15,576,085.45, accounting for -28.92% of total profit[86]. Dividend Distribution - The company plans to distribute a cash dividend of 0.05 yuan per 10 shares to all shareholders, based on a total of 430,000,000 shares[4]. - The total cash dividend distributed for 2020 was 2,150,000 yuan, representing 18.73% of the net profit attributable to shareholders[128]. - The cash dividend per 10 shares was set at 0.05 yuan (including tax) for the year 2020, consistent with the previous two years[127]. - The cash dividend accounted for 100% of the total profit distribution for the year 2020[125]. - The company has maintained a consistent cash dividend policy over the past three years, with the same amount distributed each year[128]. Operational Strategy and Innovation - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, highlighting potential risks and countermeasures in its operational outlook[4]. - The company is committed to digital innovation in healthcare, utilizing technologies such as cloud computing, big data, and artificial intelligence to enhance its service offerings[28]. - The company is actively exploring industrial financial services, leveraging its resources in the livelihood sector to serve industry chain groups[34]. - The company is focusing on expanding its market presence and business transformation in the smart IoT sector and new industry applications[57]. - The company aims to become a technology and service enterprise based on data chains, aligning with national strategies such as "Healthy China" and "Digital China"[111]. - The company is committed to continuous technological innovation to meet customer needs and improve service satisfaction[185]. Subsidiaries and Market Expansion - The company established 7 new subsidiaries in regions including Chongqing, Sichuan, Yunnan, and Tibet, enhancing market responsiveness and service levels[41]. - The company established four new subsidiaries in 2020, including 易联众健康科技有限公司 and 厦门万势顺易科技有限公司, while losing control over two subsidiaries[69][70]. - The company has developed a comprehensive service network integrating software systems, card services, and smart terminals, enhancing its overall service capabilities[37]. - The company has been recognized as a "2020 Provincial Leading Enterprise" and "Top 30 Internet Enterprises in Fujian Province"[41]. Research and Development - Research and development expenses increased by 16.37% year-on-year to 160,116,455.78 CNY, primarily due to higher personnel costs and depreciation[73]. - The company registered 265 new software copyrights, 3 invention patents, and 4 design patents during the reporting period[41]. - R&D investment amounted to CNY 201.87 million in 2020, representing 19.21% of total revenue, with capitalized R&D expenses of CNY 41.75 million, accounting for 20.68% of total R&D investment[75]. - The number of R&D personnel increased to 1,467 in 2020, making up 50.74% of the total workforce, compared to 49.11% in 2019[75]. Risk Management and Compliance - The company emphasizes the importance of reducing R&D costs and improving the competitiveness of its product systems and overall solutions[112]. - The company has taken measures to mitigate operational risks and enhance quality control in its business operations[97]. - The company has established a comprehensive independent labor, personnel, and compensation management system[132]. - The company has pledged to comply with legal and regulatory requirements to prevent any conflicts of interest[135]. Corporate Governance - All board members attended the meeting to review the annual report, ensuring comprehensive oversight of the report's content[3]. - The company has a robust internal management structure to enhance operational efficiency and reduce management risks[118]. - The company has implemented a comprehensive internal management and control system to enhance corporate governance and transparency for shareholders[184]. - The company has established an independent financial department and accounting system, ensuring compliance with regulations[133].

Financial Performance - The company's operating revenue for Q1 2021 was ¥72,362,291.17, a decrease of 20.61% compared to ¥91,146,123.32 in the same period last year[7]. - The net profit attributable to shareholders was -¥56,743,247.14, representing a decline of 14.47% from -¥49,571,851.16 year-on-year[7]. - The net cash flow from operating activities was -¥161,036,894.15, which is 11.27% worse than -¥144,730,098.23 in the previous year[7]. - The basic and diluted earnings per share were both -¥0.13, a decrease of 14.48% compared to -¥0.12 in the same period last year[7]. - The weighted average return on net assets was -8.28%, down from -7.14% year-on-year, indicating a decline of 1.14%[7]. - The net profit for the first quarter of 2021 was -19,314,661.88 CNY, compared to -28,845,379.06 CNY in the same period last year, showing an improvement of approximately 33.5%[53]. - The total comprehensive income for the first quarter was -26,725,333.73 CNY, compared to -28,845,379.06 CNY in the previous year, indicating a reduction in losses[54]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,831,066,954.77, down 0.90% from ¥1,847,676,328.41 at the end of the previous year[7]. - The net assets attributable to shareholders decreased by 8.94% to ¥653,500,596.72 from ¥717,654,515.71 at the end of the previous year[7]. - Total liabilities rose to CNY 1,004,010,873.25 from CNY 940,001,341.70, reflecting an increase of approximately 6.8%[41]. - The company's equity attributable to shareholders decreased to CNY 653,500,596.72 from CNY 717,654,515.71, a decline of about 8.9%[42]. - Current assets totaled CNY 1,125,163,932.35, down from CNY 1,154,556,923.40, indicating a decrease of about 2.6%[40]. - Total liabilities increased to CNY 996,905,585.00 from CNY 896,389,255.08[48]. - Total equity decreased to CNY 521,226,271.42 from CNY 547,951,605.15[48]. Cash Flow - Cash inflow from operating activities was 178,750,376.59 CNY, slightly up from 172,731,279.84 CNY year-on-year[57]. - The cash flow from financing activities generated a net inflow of 55,319,105.56 CNY, compared to a net outflow of -55,994,433.53 CNY in the same period last year[58]. - The net cash flow from investment activities was 23,578,843.86 CNY, a significant improvement compared to -4,952,820.97 CNY in the previous year[61]. - Cash and cash equivalents at the end of the period stood at 346,034,923.73 CNY, compared to 245,188,980.62 CNY at the end of the same period last year, reflecting an increase of approximately 41%[58]. Operational Highlights - The company received government subsidies amounting to ¥4,665,996.55 during the reporting period[8]. - The company has secured new medical insurance information platform projects in multiple provinces, enhancing its core competitiveness in the field[21]. - The company is actively developing new products and technologies, including smart hospitals and regulatory monitoring platforms[21]. - The company faces operational risks due to the expansion of its product and service categories, necessitating a robust customer service system[24]. - The company is actively developing high-tech products characterized by new infrastructure technologies such as AI, 5G, IoT, and blockchain, aiming to transition to a digital ecosystem operation model[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,197[10]. - The largest shareholder, Zhang Xi, holds 16.21% of the shares, with 69,681,649 shares, of which 52,261,237 are pledged[10]. Strategic Initiatives - The company plans to issue up to 129 million A-shares, raising a total of no more than 829.47 million yuan, which will be used to repay bank loans and supplement working capital[28]. - The company has approved the transfer of 52% equity in its subsidiary, Xiamen Yilianzhong Yifang Technology Co., Ltd., for 12.49 million yuan to optimize resource allocation and enhance operational capacity[28]. - The company emphasizes the importance of talent retention and has implemented attractive compensation mechanisms and career development plans to stabilize its core talent team[30]. - The company has engaged in discussions with institutional investors regarding its healthcare and public service business strategies[34]. Compliance and Governance - The company has not reported any violations regarding external guarantees during the reporting period[32]. - The company has not experienced any non-operational fund occupation by its controlling shareholders or related parties during the reporting period[33]. - The first quarter report has not been audited, indicating that the figures may be subject to change[70].

易联众信息技术股份有限公司 2020 年第三季度报告全文 易联众信息技术股份有限公司 2020 年第三季度报告 2020 年 10 月 1 易联众信息技术股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张曦、主管会计工作负责人陈东红及会计机构负责人(会计主管 人员)尤泽祥声明：保证季度报告中财务报表的真实、准确、完整。 2 易联众信息技术股份有限公司 2020 年第三季度报告全文 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,800,035,366.01 | 1,723,571,479.08 | | 4.44% | | 归属于上市公司股东的净资产 | 662,875,630.75 | 734 ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2020, representing a year-on-year increase of 15%[1]. - The company has set a revenue guidance of 1.2 billion RMB for the full year 2020, indicating a growth target of 10%[1]. - The company's operating revenue for the first half of 2020 was approximately ¥318.24 million, representing an increase of 18.98% compared to ¥267.48 million in the same period last year[20]. - The total profit for the reporting period was -64.7133 million yuan, a decrease of 128.35% year-on-year[43]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥46.27 million, a decrease of 192.80% from a loss of ¥15.80 million in the previous year[20]. - The overall net profit margin for the first half of 2020 was reported at 12%, a slight decrease from 14% in the same period last year[77]. - The company reported a net loss of 168,194.2 yuan from its subsidiary Anhui Yilianzhong Information Technology Co., Ltd., with a total revenue of 1,790,837.69 yuan[76]. - The company reported a comprehensive income loss of ¥377,510,000.00 during the current period[182]. User Growth and Market Expansion - User data showed an increase in active users by 20% compared to the same period last year, reaching 1.2 million users[1]. - User data showed an increase in active users by 30% compared to the previous year, reaching a total of 1.5 million[78]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2021[1]. - The company plans to expand its market presence in Southeast Asia, targeting a revenue increase of 25% in that region by the end of 2021[78]. - The company has expanded its market presence in Northeast, Northwest, and Southwest regions, focusing on product development and customer acquisition[46]. Research and Development - Research and development expenses increased by 25% to support innovation in AI technology[1]. - The company increased its research and development expenditure by 31.33% compared to the beginning of the year, reflecting a commitment to innovation[32]. - The company’s R&D investment increased by 33.09% to approximately ¥92.59 million, up from ¥69.56 million, due to intensified research activities during the reporting period[53]. - The company has obtained 75 software copyrights, 2 invention patents, and 3 design patents during the reporting period[38]. - The company has developed a facial recognition anti-fraud system to reduce the probability of medical insurance fund fraud[28]. Strategic Initiatives - A strategic acquisition of a local tech firm is expected to enhance the company's capabilities in big data analytics[1]. - The management emphasized a focus on digital transformation as a key strategy for future growth[1]. - The company is actively exploring new product development and technology application to strengthen its core competitiveness in the face of challenges posed by the COVID-19 pandemic[42]. - The company is focused on enhancing its software development capabilities and expanding its market presence in the technology sector[74]. - The company is committed to improving its financial health and operational quality through continuous risk management and strategic adjustments[74]. Financial Health and Risks - The company identified potential risks related to regulatory changes and has implemented measures to mitigate these risks[1]. - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company has seen a significant decrease in net cash flow from financing activities, with a net decrease of approximately ¥42.36 million, primarily due to reduced borrowing during the reporting period[53]. - The company has taken measures to ensure the timely implementation of its equity transfer plans, with no delays reported[73]. - The company is focused on attracting and retaining high-quality talent to address human resource risks, implementing competitive compensation and training programs[81]. Subsidiary Performance - The overall financial performance of the subsidiaries indicates a mixed result, with some subsidiaries showing profitability while others reported losses[76]. - The company’s subsidiary is actively seeking investment and partnerships to enhance its market position[129]. - The company has not experienced any major litigation or arbitration matters during the reporting period[94]. Corporate Governance and Structure - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[194]. - The company has established a new management structure combining a parent company function center, regional subsidiaries, and product subsidiaries to enhance operational flexibility and adaptability[84]. - The company has not conducted any research, communication, or interview activities during the reporting period[85]. Cash Flow and Assets - The net cash flow from operating activities was approximately -¥182.26 million, showing a slight improvement of 2.02% compared to -¥186.02 million in the same period last year[20]. - The company's cash and cash equivalents decreased by 40.18% compared to the beginning of the year, mainly due to net cash outflow from operating activities[32]. - The total assets at the end of the reporting period were approximately ¥1.70 billion, a decrease of 1.37% from ¥1.72 billion at the end of the previous year[20]. - The company's total liabilities were CNY 905,157,227.75, compared to CNY 849,402,999.52 at the end of 2019, indicating an increase of about 6.57%[160]. Compliance and Regulations - The company has complied with environmental regulations and has not faced penalties for violations during the reporting period[118]. - The company adheres to the accounting standards and has confirmed that its financial statements accurately reflect its financial position and operating results[200].

Financial Performance - The company's operating revenue for 2019 was approximately CNY 948.72 million, representing a 30.00% increase compared to CNY 729.81 million in 2018[16]. - The net profit attributable to shareholders for 2019 was CNY 10.51 million, a decrease of 28.36% from CNY 14.66 million in the previous year[16]. - The net cash flow from operating activities increased by 11.84% to CNY 63.49 million, up from CNY 56.77 million in 2018[16]. - The total assets at the end of 2019 were CNY 1,723.57 million, a decrease of 9.99% from CNY 1,914.96 million at the end of 2018[16]. - The basic earnings per share for 2019 was CNY 0.024, down 29.41% from CNY 0.034 in 2018[16]. - The company reported a significant increase in non-recurring gains, totaling CNY 18.72 million in 2019, compared to CNY 8.25 million in 2018[22]. - The company experienced a net loss of CNY 20.83 million in Q1 2019, followed by a profit of CNY 5.03 million in Q2, and a profit of CNY 16.96 million in Q3[18]. - The total liabilities decreased to CNY 989.06 million at the end of 2019, down from CNY 1,174.31 million at the end of 2018[16]. - The weighted average return on equity for 2019 was 1.44%, down from 2.00% in 2018[16]. - The company achieved a revenue of 948.72 million yuan in 2019, representing a year-on-year increase of 30.00%[41]. - Operating costs for the year were 459.68 million yuan, up 33.64% compared to the previous year[41]. - The revenue from the livelihood service sector was ¥897.43 million, accounting for 94.59% of total revenue, with a year-on-year growth of 34.01%[53]. - Custom software and IC products generated ¥609.70 million, representing 64.27% of total revenue, with a significant increase of 69.66% compared to the previous year[53]. - The company reported a significant decline in revenue from financing services, down 22.02% to ¥42.46 million[53]. - The company’s operating costs for the livelihood information service sector were ¥438.53 million, with a year-on-year increase of 35.20%[58]. - The company’s revenue from the technology service segment decreased by 19.60% to ¥98.48 million[58]. Dividend Distribution - The company plans to distribute a cash dividend of 0.05 CNY per 10 shares to all shareholders, based on a total of 430,000,000 shares[4]. - The total cash dividend distributed was 2,150,000 yuan, representing 20.46% of the net profit attributable to shareholders[116]. - The cash dividend per 10 shares was set at 0.05 yuan (including tax) for the year 2019[116]. - The company has maintained a cash dividend payout ratio of 100% of the distributable profit for the reporting period[116]. - The company did not propose any stock bonus or capital reserve transfer for the reporting period[115]. - The company has consistently distributed cash dividends of 2,150,000 yuan for the past three years, maintaining the same dividend per share[116]. - The remaining undistributed profits will be carried forward to the next fiscal year[116]. Operational Strategy and Market Presence - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, highlighting potential risks and countermeasures in its operational outlook[4]. - The report includes a detailed analysis of the company's operational performance and future development prospects, indicating a strategic focus on growth[4]. - The company has not committed to any specific performance forecasts, urging investors to recognize the difference between plans and commitments[4]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming year[16]. - The annual report outlines the company's strategic initiatives and potential market expansions, reflecting a proactive approach to growth[4]. - The company has a comprehensive structure of wholly-owned subsidiaries across various regions, enhancing its operational capabilities[8]. - The company has a diverse portfolio of subsidiaries involved in various sectors, including finance, healthcare, and technology, indicating a broad market presence[9]. - The company has maintained a leading position in the medical insurance sector, achieving several milestones such as the first provincial-level unified directory coding management system in 2004 and the first internet-based real-time settlement in 2017[26]. - The company has expanded its health medical business, focusing on health data services, smart hospitals, and community health services since 2017[27]. - The company is focused on expanding its market reach and enhancing its technological capabilities through ongoing product and technology development initiatives[96]. - The company aims to enhance its competitive advantage by rapidly responding to new industry demands and improving its service offerings[103]. - The company plans to strengthen its industry presence by exploring opportunities in healthcare, social security, and financial services, focusing on markets like medical insurance and smart IoT[104]. Research and Development - Research and development expenses increased by 30.50% to 137,592,625.26 RMB, primarily due to the rise in personnel costs[70]. - R&D investment for the year was 174,581,269.54 RMB, accounting for 18.40% of operating revenue, with 36,988,644.28 RMB capitalized[71]. - The number of R&D personnel increased to 1,302, representing 49.11% of the total workforce[71]. - The company has developed a facial recognition anti-fraud system for medical insurance, which helps reduce the probability of fund misuse[27]. - The company has developed various innovative products in the medical insurance sector, including identity verification and fraud detection systems[42]. - The company emphasizes talent management and has accelerated the recruitment of high-quality personnel to support its strategic development[38]. - The company has established a comprehensive after-sales service system to enhance its brand image and address operational challenges as its product and service offerings expand[105]. Governance and Compliance - The report confirms that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, ensuring transparency[3]. - The company has established independent governance structures, including a shareholders' meeting and board of directors[123]. - The company is committed to avoiding any competitive business activities that may directly or indirectly compete with its operations[123]. - The company has taken measures to ensure that its assets are entirely under its control and not used to guarantee debts of other enterprises[121]. - The company has a clear policy to minimize related party transactions with other enterprises under personal control[122]. - The company has a commitment to independent tax payment practices[121]. - The company has not experienced any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[129]. Subsidiaries and Investments - The company established 9 new subsidiaries during the reporting period, including Shaanxi Yilianzhong Jinna Information Technology Co., Ltd. and Hunan Yilianzhong Xinwei Information Technology Co., Ltd.[65]. - The company disposed of two subsidiaries, losing control over them, and also deregistered one subsidiary during the reporting period[135]. - The overall performance of subsidiaries indicates a mixed financial outlook, with some reporting losses while others show growth potential in their respective markets[92]. - The company is positioned as the total integrator for the Sanming medical reform and the general contractor for the provincial medical insurance informationization, which is expected to enhance its market presence[97]. - The company’s investment in new subsidiaries is expected to enhance its overall operational capabilities and profitability[95]. Shareholder Information - The controlling shareholder, Zhang Xi, transferred 36,775,000 shares, representing 8.552% of the total share capital, to optimize the shareholding structure[166]. - As of the report date, Zhang Xi holds a total of 86,065,867 shares, accounting for 20.02% of the company's total share capital[168]. - The controlling shareholder, Mr. Zhang Xi, pledged 36,775,000 shares on April 3, 2019, and later engaged in stock repurchase transactions involving 69,606,549 shares on September 20, 2019[169][170]. - The company’s board of directors accepted the resignation of independent director Ms. Zhan Yiwen on November 25, 2019, due to personal reasons[176]. - The company’s controlling shareholder engaged in multiple stock pledge and repurchase transactions throughout 2019, indicating active management of shareholding structure[169][170][171][172]. Government Relations and Social Responsibility - The company actively fulfills its social responsibilities and maintains transparency in shareholder communications, ensuring rights for minority shareholders[162]. - The company and its subsidiaries complied with environmental protection laws and did not face any penalties for violations during the reporting period[165]. - The government has emphasized the importance of healthcare informationization, with policies promoting the integration of internet technology in healthcare services[100]. - The company is responding to the urgent financing needs of the healthcare industry, as traditional funding sources are becoming limited[102]. - Policies have been introduced to facilitate financing leasing for medical equipment, indicating a shift towards more flexible funding solutions in the healthcare sector[102].